Have you been paying attention to shares of Labcorp Holdings (LH - Free Report) ? Shares have been on the move with the stock up 9.3% over the past month. The stock hit a new 52-week high of $298.46 in the previous session. Labcorp has gained 16% since the start of the year compared to the -0.1% move for the Zacks Medical sector and the -1.8% return for the Zacks Medical Services industry.
What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, having beaten the Zacks Consensus Estimate in each of the last four quarters. In its last earnings report on April 30, 2026, Labcorp reported EPS of $4.25 versus consensus estimate of $4.09.
For the current fiscal year, Labcorp is expected to post earnings of $18 per share on $14.71 in revenues. This represents a 9.49% change in EPS on a 5.43% change in revenues. For the next fiscal year, the company is expected to earn $19.33 per share on $15.44 in revenues. This represents a year-over-year change of 7.36% and 4.99%, respectively.
Valuation MetricsLabcorp may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.
On this front, we can look at the Zacks Style Scores, as they provide investors with an additional way to sort through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.
Labcorp has a Value Score of B. The stock's Growth and Momentum Scores are B and C, respectively, giving the company a VGM Score of A.
In terms of its value breakdown, the stock currently trades at 16.2X current fiscal year EPS estimates, which is a premium to the peer industry average of 16X. On a trailing cash flow basis, the stock currently trades at 11.7X versus its peer group's average of 10X. Additionally, the stock has a PEG ratio of 1.93. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
Zacks RankWe also need to consider the stock's Zacks Rank, as this supersedes any trend on the style score front. Fortunately, Labcorp currently has a Zacks Rank of #2 (Buy) thanks to rising earnings estimates.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Labcorp passes the test. Thus, it seems as though Labcorp shares could have a bit more room to run in the near term.
How Does LH Stack Up to the Competition?Shares of LH have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is Progyny, Inc. (PGNY - Free Report) . PGNY has a Zacks Rank of #1 (Strong Buy) and a Value Score of C, a Growth Score of A, and a Momentum Score of C.
Earnings were strong last quarter. Progyny, Inc. beat our consensus estimate by 13.64%, and for the current fiscal year, PGNY is expected to post earnings of $2.04 per share on revenue of $1.38 billion.
Shares of Progyny, Inc. have gained 12.1% over the past month, and currently trade at a forward P/E of 15.05X and a P/CF of 41.7X.
The Medical Services industry is in the top 39% of all the industries we have in our universe, so it looks like there are some nice tailwinds for LH and PGNY, even beyond their own solid fundamental situation.
Labcorp (LH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Labcorp Holdings (LH - Free Report) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 30. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus EstimateThis medical laboratory operator is expected to post quarterly earnings of $4.79 per share in its upcoming report, which represents a year-over-year change of +10.1%.
Revenues are expected to be $3.72 billion, up 5.4% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.11% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Labcorp?For Labcorp, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +0.71%.
On the other hand, the stock currently carries a Zacks Rank of #2.
So, this combination indicates that Labcorp will most likely beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Labcorp would post earnings of $4.09 per share when it actually produced earnings of $4.25, delivering a surprise of +3.91%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Labcorp appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Key Takeaways Labcorp is expected to post Q2 revenue growth of 5.4% and EPS growth of 10.1% year over year.LH expanded diagnostics through partnerships, acquisitions and new oncology, neurology and consumer tests.Labcorp likely saw BLS support from Central Laboratories as Early Development streamlining continued. Labcorp Holdings Inc. (LH - Free Report) , or Labcorp, is slated to report its second-quarter 2026 results on July 30, before the market opens.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of $4.25, surpassing the Zacks Consensus Estimate by 3.91%. Labcorp outpaced estimates in each of the trailing four quarters, the average surprise being 3.31%.
Q2 Estimates for LHThe Zacks Consensus Estimate for Labcorp’s second-quarter 2026 revenues is pegged at $3.72 billion. This suggests a 5.4% rise from the year-ago reported figure.
The Zacks Consensus Estimate for second-quarter EPS indicates an improvement of 10.1% to $4.79. The estimate has remained unchanged in the past 60 days.
Here's a quick review of the company’s performance leading up to its second-quarter earnings.
What Could Shape Labcorp's Q2 Results?In the second quarter of 2026, Diagnostics Laboratories’ (Dx) performance is likely to have continued to witness strong organic contribution. Labcorp's ongoing expansion through health system partnerships and acquisitions is expected to have supported testing volumes by broadening its patient and provider network. During the quarter, the company announced a nationwide strategic collaboration with Children's Hospital of Philadelphia to expand access to advanced diagnostics for pediatric patients.
In May, Labcorp launched an expanded DPYD Genotyping test to identify cancer patients at risk for severe chemotherapy side effects. Earlier in March, it acquired the select assets of Crouse Health's Laboratory Alliance of Central New York and executed an agreement to manage Crouse Health’s inpatient laboratories. All these developments are expected to have favorably boosted the quarter’s top line.
The company’s expanding specialty testing portfolio likely remained another tailwind. These tests are focused in the areas spanning oncology, women's health, neurology and autoimmune disease, which are projected to far outpace the broader diagnostics market. In second-quarter 2026, Oncology results are likely to have benefited from the launch of several liquid biopsy tests and expanded access to molecular residual disease (MRD) solutions.
Labcorp further strengthened the portfolio by launching Agilent Technologies' FDA-approved companion diagnostic to identify patients with platinum-resistant ovarian cancer who may be eligible for Merck's KEYTRUDA. The company’s market-leading Alzheimer's testing portfolio may have boosted Neurology revenues.
Beyond the core testing, the company also introduced the first FDA-cleared rapid fentanyl test of its kind made in the United States, delivering results in just 10 minutes. The Labcorp OnDemand platform is also expected to have favorably supported revenues, driven by strong demand across its expanding menu of consumer health tests.
Labcorp may have also benefited from its ongoing use of advanced technologies, including AI and robotics, to enhance customer experiences and productivity. In April, the company expanded its collaboration with Epic, making its full test menu available through the Aura platform. Other recent initiatives include the development of an AI-powered real-world data platform with Amazon Web Services and Datavant to accelerate Alzheimer's research and a strategic collaboration with Optum.ai to streamline laboratory operations. Collectively, all these factors are expected to have positively impacted Labcorp’s second-quarter revenues.
The Zacks Consensus Estimate expects Dx revenues to grow 6.1% year over year.
Within the Biopharma Laboratory Services (“BLS”) segment,Labcorp has likely benefited from the solid performance of Central Laboratories. The company may have also progressed with its strategic actions to streamline the Early Development business, which may have limited overall growth.
The Zacks Consensus Estimate suggests that BLS revenues will grow 2.7% year over year.
Earnings Whispers for LabcorpPer our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is exactly the case here, as you can see below:
Earnings ESP: Labcorp has an Earnings ESP of +0.71%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Other Key MedTech PicksHere are some other medical stocks worth considering, as these also have the right combination of elements to post an earnings beat this time:
CVS Health (CVS - Free Report) has an Earnings ESP of +1.42% and a Zacks Rank #2. The company is slated to release second-quarter 2026 results on Aug. 5.
CVS’ earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.79%. The Zacks Consensus Estimate expects the company’s second-quarter EPS to increase 3.3% from the year-ago quarter’s figure.
Henry Schein (HSIC - Free Report) has an Earnings ESP of +0.41% and a Zacks Rank #2. The company is expected to release second-quarter 2026 results soon.
HSIC’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.74%. The Zacks Consensus Estimate for the company’s second-quarter EPS calls for a rise of 10.9% from the year-ago quarter’s figure.
Alcon (ALC - Free Report) has an Earnings ESP of +3.13% and a Zacks Rank #2. The company is slated to release second-quarter 2026 results on Aug. 10.
ALC’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.66%. The Zacks Consensus Estimate anticipates the company’s second-quarter EPS to increase 1.3% from the year-ago quarter’s figure.
Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Labcorp Holdings (LH - Free Report) , which belongs to the Zacks Medical Services industry, could be a great candidate to consider.
This medical laboratory operator has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 3.47%.
For the most recent quarter, Labcorp was expected to post earnings of $4.09 per share, but it reported $4.25 per share instead, representing a surprise of 3.91%. For the previous quarter, the consensus estimate was $3.95 per share, while it actually produced $4.07 per share, a surprise of 3.04%.
Price and EPS Surprise
Thanks in part to this history, there has been a favorable change in earnings estimates for Labcorp lately. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the stock is positive, which is a great indicator of an earnings beat, particularly when combined with its solid Zacks Rank.
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Labcorp has an Earnings ESP of +0.71% at the moment, suggesting that analysts have grown bullish on its near-term earnings potential. When you combine this positive Earnings ESP with the stock's Zacks Rank #2 (Buy), it shows that another beat is possibly around the corner. The company's next earnings report is expected to be released on July 30, 2026.
Investors should note, however, that a negative Earnings ESP reading is not indicative of an earnings miss, but a negative value does reduce the predictive power of this metric.
Many companies end up beating the consensus EPS estimate, but that may not be the sole basis for their stocks moving higher. On the other hand, some stocks may hold their ground even if they end up missing the consensus estimate.
Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
California Public Employees Retirement System decreased its position in Labcorp Holdings Inc. (NYSE:LH – Free Report) by 8.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 195,176 shares of the medical research company’s stock after selling 18,270 shares during the quarter. California Public Employees Retirement System owned 0.24% of Labcorp worth $52,075,000 at the end of the most recent reporting period.
Several other institutional investors have also recently added to or reduced their stakes in LH. Vanguard Group Inc. increased its holdings in shares of Labcorp by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 9,850,631 shares of the medical research company’s stock worth $2,471,326,000 after buying an additional 37,197 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Labcorp by 103.1% in the 4th quarter. Victory Capital Management Inc. now owns 5,356,825 shares of the medical research company’s stock worth $1,343,922,000 after acquiring an additional 2,719,475 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in shares of Labcorp by 1.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,226,446 shares of the medical research company’s stock worth $607,241,000 after acquiring an additional 22,170 shares in the last quarter. Geode Capital Management LLC grew its position in Labcorp by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 2,137,010 shares of the medical research company’s stock worth $534,023,000 after acquiring an additional 13,775 shares during the last quarter. Finally, Wellington Management Group LLP grew its position in Labcorp by 15.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,105,791 shares of the medical research company’s stock worth $604,488,000 after acquiring an additional 289,029 shares during the last quarter. 95.94% of the stock is owned by institutional investors.
Labcorp Trading Down 0.9% Shares of LH opened at $280.86 on Tuesday. The company has a quick ratio of 1.54, a current ratio of 1.73 and a debt-to-equity ratio of 0.68. Labcorp Holdings Inc. has a 12-month low of $241.81 and a 12-month high of $293.72. The firm has a market capitalization of $23.03 billion, a PE ratio of 24.88, a price-to-earnings-growth ratio of 1.88 and a beta of 0.89. The stock’s fifty day simple moving average is $266.74 and its 200-day simple moving average is $268.21.
Labcorp (NYSE:LH – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $4.09 by $0.16. The firm had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.51 billion. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The company’s revenue was up 5.8% on a year-over-year basis. During the same period last year, the company earned $3.84 earnings per share. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. As a group, research analysts predict that Labcorp Holdings Inc. will post 18 earnings per share for the current year.
Labcorp Announces Dividend The firm also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 28th will be given a dividend of $0.72 per share. The ex-dividend date is Friday, August 28th. This represents a $2.88 annualized dividend and a dividend yield of 1.0%. Labcorp’s payout ratio is currently 25.51%.
Insider Transactions at Labcorp In related news, EVP Bryan T. Vaughn sold 234 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total transaction of $66,968.46. Following the completion of the sale, the executive vice president directly owned 6,746 shares of the company’s stock, valued at $1,930,637.74. The trade was a 3.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Adam H. Schechter sold 5,903 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $254.50, for a total transaction of $1,502,313.50. Following the completion of the transaction, the chief executive officer owned 107,234 shares in the company, valued at $27,291,053. This represents a 5.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 6,991 shares of company stock worth $1,796,696 in the last quarter. 0.84% of the stock is owned by company insiders.
Analyst Ratings Changes LH has been the subject of several research analyst reports. Weiss Ratings reiterated a “buy (b-)” rating on shares of Labcorp in a research report on Friday, May 8th. Evercore restated an “outperform” rating and issued a $300.00 target price on shares of Labcorp in a research note on Wednesday, April 8th. Bank of America lifted their price target on Labcorp from $300.00 to $320.00 and gave the company a “buy” rating in a report on Monday, July 13th. Wall Street Zen upgraded shares of Labcorp from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Finally, Robert W. Baird increased their price objective on shares of Labcorp from $335.00 to $338.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Nine investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $314.40.
Check Out Our Latest Analysis on LH
About Labcorp (Free Report)
Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.
Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.
Featured Stories Five stocks we like better than Labcorp The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story
Receive News & Ratings for Labcorp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Labcorp and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEFifth Third Bancorp Buys New Stake in Morgan Stanley Pathway Large Cap Equity ETF $MSLC
NEXT HEADLINE »Bessemer Group Inc. Purchases 36,940 Shares of CONMED Corporation $CNMD
D.A. Davidson & CO. increased its holdings in shares of Labcorp Holdings Inc. (NYSE:LH – Free Report) by 17.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,575 shares of the medical research company’s stock after acquiring an additional 2,824 shares during the quarter. D.A. Davidson & CO.’s holdings in Labcorp were worth $4,956,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of the business. Thurston Springer Miller Herd & Titak Inc. bought a new position in shares of Labcorp during the fourth quarter valued at approximately $26,000. Hilton Head Capital Partners LLC bought a new stake in shares of Labcorp in the 4th quarter worth approximately $27,000. JPL Wealth Management LLC bought a new stake in shares of Labcorp in the 3rd quarter worth approximately $28,000. Eagle Bay Advisors LLC acquired a new position in Labcorp during the 4th quarter valued at approximately $29,000. Finally, DV Equities LLC acquired a new position in Labcorp during the 4th quarter valued at approximately $29,000. Institutional investors own 95.94% of the company’s stock.
Labcorp Stock Performance Shares of NYSE LH opened at $283.63 on Friday. Labcorp Holdings Inc. has a 12-month low of $241.81 and a 12-month high of $293.72. The company has a market cap of $23.26 billion, a PE ratio of 25.12, a P/E/G ratio of 1.88 and a beta of 0.89. The stock has a 50 day simple moving average of $266.22 and a 200-day simple moving average of $267.91. The company has a current ratio of 1.73, a quick ratio of 1.54 and a debt-to-equity ratio of 0.68.
Labcorp (NYSE:LH – Get Free Report) last posted its earnings results on Thursday, April 30th. The medical research company reported $4.25 EPS for the quarter, beating the consensus estimate of $4.09 by $0.16. The firm had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.51 billion. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The firm’s revenue was up 5.8% compared to the same quarter last year. During the same period last year, the firm earned $3.84 EPS. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. On average, equities research analysts forecast that Labcorp Holdings Inc. will post 18 EPS for the current year.
Labcorp Announces Dividend The firm also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 28th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Friday, August 28th. Labcorp’s dividend payout ratio (DPR) is 25.51%.
Wall Street Analysts Forecast Growth A number of brokerages recently commented on LH. Robert W. Baird upped their price objective on Labcorp from $335.00 to $338.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Evercore reissued an “outperform” rating and set a $300.00 price target on shares of Labcorp in a report on Wednesday, April 8th. Bank of America upped their price target on shares of Labcorp from $300.00 to $320.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Wall Street Zen upgraded shares of Labcorp from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Labcorp in a report on Friday, May 8th. Nine research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $314.40.
Check Out Our Latest Research Report on LH
Insider Activity In related news, EVP Kathryn W. Kyle sold 762 shares of Labcorp stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $263.89, for a total transaction of $201,084.18. Following the sale, the executive vice president directly owned 3,813 shares in the company, valued at $1,006,212.57. The trade was a 16.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Adam H. Schechter sold 5,903 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $254.50, for a total transaction of $1,502,313.50. Following the completion of the sale, the chief executive officer directly owned 107,234 shares of the company’s stock, valued at $27,291,053. The trade was a 5.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 6,991 shares of company stock valued at $1,796,696. Company insiders own 0.84% of the company’s stock.
Labcorp Company Profile (Free Report)
Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.
Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.
See Also Five stocks we like better than Labcorp Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs? The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Labcorp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Labcorp and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEGeneos Wealth Management Inc. Sells 7,627 Shares of ExxonMobil Corporation $XOM
NEXT HEADLINE »Cornerstone Advisory LLC Has $3.49 Million Stake in ExxonMobil Corporation $XOM
SummaryLabcorp remains a buy consideration, leveraging a successful rollup strategy in a fragmented laboratory testing industry for steady, predictable growth.Automation is driving cost reductions in LH’s operations. That cost reduction helps offset healthcare pricing pressures.With a larger scale, LH now targets single-digit growth and a total return around 10%, prioritizing predictability over rapid expansion.Risks are low due to recurring revenue, minimal acquisition disruption, and the sector’s resilience.This is probably one of the more predictable businesses that I follow.This idea was discussed in more depth with members of my private investing community, Oil & Gas Value Research. Learn More » JHVEPhoto/iStock Editorial via Getty Images
The last article that I wrote on Labcorp (LH) mentioned the fact that this company was basically set up as a "rollup corporation". It was going to grow by acquiring smaller "mom and pop" sized operations
25.85K Followers
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in LH over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Disclaimer: I am not a registered investment advisor and this article reflects my own opinions. I do not and will not advise anyone to invest or not invest in this stock. You have to do your own due diligence and your own homework, by reading the company's filings and press releases, as well as any other relevant information to make up your own mind at your own risk. Your investments must match your own risk profile as well as your desire to take on risk and the patience to see out situations such as this.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Labcorp Holdings (LH - Free Report) Headquartered in Burlington, NC, Labcorp Holdings, Inc. or Labcorp, is a leading healthcare diagnostics company, providing comprehensive clinical laboratory services and end-to-end drug development support. In 2015, Labcorp acquired NJ based Covance, a drug development services company providing a wide range of early stage and late-stage product development services on a worldwide basis primarily to the pharmaceutical and biotechnology industries.
LH is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 15.38; value investors should take notice.
One analyst revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.01 to $18.00 per share. LH boasts an average earnings surprise of +3.3%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, LH should be on investors' short list.
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on September 11, 2026, to stockholders of record as of the close of business on August 28, 2026.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025, and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Labcorp Holdings (LH - Free Report) Headquartered in Burlington, NC, Labcorp Holdings, Inc. or Labcorp, is a leading healthcare diagnostics company, providing comprehensive clinical laboratory services and end-to-end drug development support. In 2015, Labcorp acquired NJ based Covance, a drug development services company providing a wide range of early stage and late-stage product development services on a worldwide basis primarily to the pharmaceutical and biotechnology industries.
LH is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.
Momentum investors should take note of this Medical stock. LH has a Momentum Style Score of B, and shares are up 8.5% over the past four weeks.
One analyst revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.01 to $18.00 per share. LH also boasts an average earnings surprise of +3.3%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, LH should be on investors' short list.
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2026 before the market opens on Thursday, July 30, 2026. The company will host a webcast beginning at 9:00 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the "News & Events" section of the Labcorp Investor Relations website at https://ir.labcorp.com. A link to the earnings webcast will also be available on the investor relations website.
A replay of the webcast will be available on the "News & Events" section of the investor relations website after the conclusion of the live event and will be available for one year.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025, and performed more than 750 million tests for patients around the world. Learn more at https://www.labcorp.com/.
Key Takeaways Labcorp is expanding oncology, neurology and genetic testing to support long-term growth.LH's Q1 2026 revenues increased 5.8%, aided by acquisitions, partnerships and network expansion.Labcorp's AI, automation and launchpad savings initiatives aim to improve efficiency and margins. Labcorp Holdings Inc. (LH - Free Report) , or Labcorp, is well-poised for growth in the coming quarters owing to its progress on its strategic priority to lead in important specialty testing areas, which are growth drivers for both its businesses. Strategic partnerships and acquisitions help the company broaden its patient and provider network while deepening its presence in key markets. Additionally, it leverages AI and technology to enhance margins and customer experience. Yet, macroeconomic pressures and adverse currency swings pose risks for Labcorp.
In the past year, this Zacks Rank #2 (Buy) stock has risen 3.2% compared with 2.2% growth of the industry and a 23.3% increase of the S&P 500 Composite.
The renowned healthcare diagnostics company has a market capitalization of $21.20 billion. Labcorp’s earnings yield of 6.9% is well ahead of the industry’s 4.3% yield. In the trailing four quarters, the company delivered an average earnings surprise of 3.31%.
Let’s delve deeper.
Tailwinds Supporting LH StockTargeted Development in High-Growth Areas: Labcorp’s continued expansion in faster-growing specialty testing areas, such as oncology, women’s health, autoimmune disease and neurology, is strengthening its growth profile. In the first quarter of 2026, Neurology delivered double-digit growth, driven by an expanded Alzheimer's testing portfolio. Oncology benefited from several newly launched liquid biopsy tests and wider availability of MRD solutions. The MRD portfolio includes the Plasma Detect ID for patients with stage I–III breast cancer or stage I–IIIA non-small cell lung cancer, as well as the Labcorp Plasma Detect Genome for stage III colon cancer, which is now available nationwide.
Image Source: Zacks Investment Research
The integration of Invitae has further expanded the company’s reach in genetic testing solutions. Labcorp is also collaborating with Illumina to advance precision oncology through applications of next-generation sequencing (NGS) solutions across the healthcare ecosystem. The Labcorp OnDemand consumer health platform delivered double-digit growth in the first quarter, supported by its expanded offerings.
Strategic Acquisitions and Partnerships to Drive Growth: In recent years, Labcorp has built a significant number of strategic relationships with health systems and regional/local laboratories, expanding its patient and provider network, and strengthening its presence in key markets. In the first quarter of 2026, enterprise revenues grew 5.8% year over year, with net acquisitions contributing 1.4%.
Recent activities include the purchase of select assets of Crouse Health’s Laboratory Alliance of Central New York’s (Lab Alliance) laboratory business and an agreement to manage their daily inpatient lab operations. Labcorp also acquired select assets of New York-based Empire City Laboratories, became the first U.S. commercial laboratory with an agreement to implement Roche’s cobas Mass Spec solution, and signed a new multi-year partnership agreement with SOMOS.
Focus on Operational Efficiency: The company continues to benefit from its launchpad initiatives, which target $100-$125 million in savings annually. In the first quarter of 2026, Labcorp expanded its collaboration with PathAI to deploy an FDA-cleared digital pathology platform across its national anatomic pathology labs and hospital lab partnerships. Together with Amazon Web Services and Datavant, the company is developing a new AI-powered real-world data platform to accelerate Alzheimer's research. More recently, Labcorp teamed up with Optum.ai to simplify laboratory operations by advancing AI.
Across its core operations, AI and automation are already deployed in areas such as pathology, cytology and microbiology. Labcorp’s generative AI tool, Test Finder, is designed to simplify lab test selection and is also integrated into Labcorp Diagnostic Assistant.
What Ails Labcorp?Macroeconomic Risks: Labcorp’s operations are heavily dependent on the demand for diagnostic testing and drug development services from patients, physicians, hospitals, medical device companies, and others. In recent times, volatilities in global economic conditions, including inflation, have significantly reduced the demand for these services, affecting the customers’ ability to pay and, consequently, the profitability of the company. Added to this, the escalation of the present geopolitical tensions and retaliatory tariffs is putting pressure on the supply chain and services, increasing the prices of offerings. In the first quarter of 2026, the cost of revenues went up 5.3% year over year.
Exposed to Currency Headwind: Labcorp's huge exposure in international markets makes it vulnerable to currency fluctuations. With the recent upward trend observed in the value of the U.S. dollar, further acceleration expected by analysts in this value will cause the company’s revenues to face a tough situation overseas.
LH Stock’s Estimate TrendThe Zacks Consensus Estimate for Labcorp’s 2026 earnings per share (EPS) has increased 1 cent to $18.00 in the past 30 days.
The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $14.71 billion, implying 5.4% growth compared to the last year.
Other Key PicksSome other top-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Align Technology (ALGN - Free Report) and Integra LifeSciences (IART - Free Report) .
Globus Medical has an earnings yield of 5.9% compared with the industry’s negative 3.5% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 26.3%. GMED shares have rallied 39.2% against the industry’s 7.5% decline over the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology, sporting a Zacks Rank #1, has an estimated long-term earnings growth rate of 10.3% compared with the industry’s 5.5% growth. Shares of the company have dipped 9% against the industry’s 6.9% growth. ALGN’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 7.8%.
Integra LifeSciences, carrying a Zacks Rank #2, has an earnings yield of 13.6% against the industry’s negative 3.5% yield. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 16.7%. IART shares have rallied 45.5% against the industry’s 7.4% decline over the past year.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +24% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Labcorp Holdings (LH - Free Report) Headquartered in Burlington, NC, Labcorp Holdings, Inc. or Labcorp, is a leading healthcare diagnostics company, providing comprehensive clinical laboratory services and end-to-end drug development support. In 2015, Labcorp acquired NJ based Covance, a drug development services company providing a wide range of early stage and late-stage product development services on a worldwide basis primarily to the pharmaceutical and biotechnology industries.
LH is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 14.73; value investors should take notice.
Nine analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.39 to $18.00 per share. LH also boasts an average earnings surprise of +3.3%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, LH should be on investors' short list.
First FDA-approved, at-home screening test that uses RNA technology to detect biomarkers associated with colorectal cancer and advanced adenomas Designed to reduce common barriers to at-home screening with a cleaner, simplified collection experience that minimizes sample handling Meets screening guidelines from the American Cancer Society (ACS) and National Comprehensive Cancer Network (NCCN) , /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of ColoSense®, the only RNA-based at-home test for colorectal cancer (CRC) screening approved by the U.S. Food and Drug Administration (FDA). Offered through a commercial collaboration with test developer Geneoscopy, ColoSense expands Labcorp's comprehensive portfolio of colorectal cancer screening solutions. The test is now covered for eligible Medicare and Medicare Advantage beneficiariesi following the Centers for Medicare & Medicaid Services (CMS) update to the National Coverage Determination (NCD) in June, with additional commercial coverage also available.
Photo courtesy of Labcorp Reducing Barriers to At-Home Screening
Colorectal cancer is highly preventable when detected early, yet approximately 4 in 10 eligible adults are not up to date with recommended screenings. While at-home tests offer convenience, the collection process can be a significant barrier to completion. According to Labcorp research, among users of at-home screening tests, 41% were uncomfortable preparing the sample, and 34% said the process felt messy. ColoSense is designed to reduce common barriers to at-home screening with a cleaner, simplified collection experience that minimizes sample handling.
"Labcorp is focused on improving colorectal cancer screening rates by offering at-home options consumers are more likely to complete," said Dr. Brian Caveney, chief medical and scientific officer at Labcorp. "With ColoSense now available nationwide, we're expanding access to an FDA-approved screening option that delivers advanced science and a more streamlined, easier-to-use collection experience."
Breakthrough Innovation Recognized by the FDA and Leading Cancer Authorities
ColoSense uses RNA-based technology to detect biomarkers associated with both colorectal cancer and advanced adenomas, precancerous changes that may be an early indication of disease. ColoSense received Breakthrough Device Designation from the FDA, which is reserved for medical devices that offer the potential for more effective diagnosis or treatment of life-threatening conditions. ColoSense aligns with stool-based RNA screening approaches recognized in the American Cancer Society (ACS) colorectal cancer screening guidelines and is included as a recommended screening option in the National Comprehensive Cancer Network (NCCN) guidelines.
"ColoSense reflects years of scientific innovation focused on improving how we screen for colorectal cancer at home," said Matt Sargent, chief commercial officer at Geneoscopy. "We're proud to partner with Labcorp to help bring this test into routine care nationwide and ensure more patients can benefit from earlier detection."
ColoSense is available through healthcare providers for adults aged 45 to 85 at average risk and is not for individuals with a history of colorectal cancer or certain high-risk conditions. ColoSense has demonstrated strong clinical performance, with 93% sensitivity for colorectal cancer in average-risk individuals, and achieved 100% sensitivityii for stage I colorectal cancer, detecting disease at its most treatable stage.
Once ordered, the collection kit is delivered directly to the consumer's home for collection and return, featuring a simplified design that eliminates the need to separate or mix the stool sample. Geneoscopy offers patient navigation support to help individuals understand their results and follow recommended next steps, including colonoscopy after a positive result. ColoSense is a screening test and does not replace diagnostic colonoscopy.
The introduction of ColoSense further expands Labcorp's portfolio of colorectal cancer screening options, providing patients and providers with greater choice and flexibility. To learn more, visit https://www.labcorp.com/treatment-areas/colorectal-cancer/crc-screening/colosense.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.
About Geneoscopy, Inc.
Geneoscopy Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy's mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. In partnership with leading universities and biopharmaceutical companies, Geneoscopy is also developing diagnostic tests for treatment selection and therapy monitoring in other GI disease areas. For more information, visit www.geneoscopy.com and follow the company on LinkedIn.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements with respect to the expected utility and benefits, and availability from Labcorp, of the ColoSense screening test for colorectal cancer.
Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.
The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS."
iPatient Criteria: Age 45 to 85 years; asymptomatic (no signs or symptoms of colorectal disease including but not limited to lower gastrointestinal pain, blood in stool, positive guaiac fecal occult blood test (gFOBT) or fecal immunochemical test (FIT)); and at average risk of developing colorectal cancer (no personal history of adenomatous polyps, colorectal cancer, or inflammatory bowel disease, including Crohn's Disease and ulcerative colitis; no family history of colorectal cancers or adenomatous polyps, familial adenomatous polyposis, or hereditary nonpolyposis colorectal cancer).
Investors looking for stocks in the Medical Services sector might want to consider either Labcorp Holdings (LH - Free Report) or Charles River Laboratories (CRL - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.
Right now, Labcorp Holdings is sporting a Zacks Rank of #2 (Buy), while Charles River Laboratories has a Zacks Rank of #3 (Hold). Investors should feel comfortable knowing that LH likely has seen a stronger improvement to its earnings outlook than CRL has recently. But this is only part of the picture for value investors.
Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.
LH currently has a forward P/E ratio of 14.78, while CRL has a forward P/E of 16.99. We also note that LH has a PEG ratio of 1.86. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. CRL currently has a PEG ratio of 2.14.
Another notable valuation metric for LH is its P/B ratio of 2.51. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, CRL has a P/B of 3.07.
These metrics, and several others, help LH earn a Value grade of B, while CRL has been given a Value grade of C.
LH stands above CRL thanks to its solid earnings outlook, and based on these valuation figures, we also feel that LH is the superior value option right now.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.93% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Labcorp Holdings (LH - Free Report) Headquartered in Burlington, NC, Labcorp Holdings, Inc. or Labcorp, is a leading healthcare diagnostics company, providing comprehensive clinical laboratory services and end-to-end drug development support. In 2015, Labcorp acquired NJ based Covance, a drug development services company providing a wide range of early stage and late-stage product development services on a worldwide basis primarily to the pharmaceutical and biotechnology industries.
LH is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 14.56; value investors should take notice.
For fiscal 2026, two analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.02 to $17.67 per share. LH boasts an average earnings surprise of +3.1%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, LH should be on investors' short list.
Labcorp Holdings (NYSE:LH) shares are up, up 1.46%, on Thursday as the company reported strong first-quarter results and raised its full-year guidance.
The stock’s positive movement follows an announcement that the company is committed to a disciplined allocation of capital, including significant investments in acquisitions and stock repurchases.
• Labcorp Holdings stock is showing upward movement. Why is LH stock trading higher?
Labcorp Q1 Results BeatLabCorp reported quarterly adjusted earnings of $4.25 per share, beating the consensus of $4.09. Sales jumped 5.8% to $3.54 billion, surpassing the consensus of $3.51 billion.
Technology Investments Drive Operational Momentum“Labcorp delivered another quarter of strong results, with robust growth and double-digit Adjusted EPS growth driven by continued momentum across our Diagnostics and Central Laboratory businesses,” said Adam Schechter, chairman and CEO of Labcorp.
“Our investments in advanced technologies, including robotics and AI, are improving the customer experience and transforming the way we operate. Driven by continued progress across our strategic priorities, we are raising our full-year Adjusted EPS guidance to $18.03 at the midpoint of the range, an increase of $0.13,” Schechter added on Thursday.
Guidance Raised Across Earnings and RevenueLabcorp raised fiscal 2026 adjusted earnings guidance from $17.55-$18.25 per share to $17.70-$18.35, compared to the consensus of $17.87.
The laboratory services provider increased 2026 sales guidance from $14.61 billion-$14.79 billion to $14.65 billion-$14.80 billion compared to the consensus of $14.66 billion.
LH Technical Outlook: Key Support, Resistance and MomentumLabcorp is currently trading within its 52-week range, positioned at $263.64, which is approximately 10% below its 52-week high of $293.72.
The stock is trading 1.5% below its 20-day simple moving average (SMA) and 2.7% below its 50-day SMA, suggesting a slight short-term bearish trend.
The 100-day SMA is also above the current price, indicating that the stock has struggled to maintain upward momentum recently.
The relative strength index (RSI) is at 37.57, suggesting neutral momentum, while the moving average convergence divergence (MACD) is below the signal line, indicating bearish pressure.
Key Resistance: $280 — This level may act as a barrier for upward movement. Key Support: $260.50 — A drop below this level could signal further weakness. How Labcorp Ranks On Value and Quality MetricsBelow is the Benzinga Edge scorecard for Labcorp Holdings, highlighting its strengths and weaknesses compared to the broader market:
Value: 31.93 — The stock is trading at a moderate valuation relative to peers. Quality: 65.19 — Indicates a solid balance sheet and operational efficiency. The Verdict: Labcorp Holdings’s Benzinga Edge signal reveals a balanced scorecard, with strong quality metrics but moderate value positioning. This suggests the company is well-managed but may face challenges in terms of valuation relative to growth prospects.
LH Stock Price Activity: Labcorp shares were up 1.46% at $261.10 at the time of publication on Thursday, according to Benzinga Pro data.
Photo via Shutterstock
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs
Key Takeaways Labcorp reported Q1 EPS of $4.25 and revenues of $3.54B, both beating estimates and rising year over year. LH saw growth across Diagnostics and Biopharma segments, driven by organic gains, volumes and FX tailwinds. Labcorp raised 2026 revenue and EPS guidance following strong results and ongoing strategic initiatives. Labcorp Holdings (LH - Free Report) or Labcorp reported first-quarter 2026 adjusted earnings per share (EPS) of $4.25, which beat the Zacks Consensus Estimate by 3.8%. The figure rose 10.6% from the year-ago level.
The adjusted figure excludes the impact of certain amortization expenses and restructuring charges, among others.
On a GAAP basis, EPS was $3.35 compared with $2.52 in the year-ago period.
LH RevenuesFirst-quarter revenues rose 5.8% year over year to $3.54 billion. The figure surpassed the Zacks Consensus Estimate by 1%.
The year-over-year increase was driven by organic revenue growth of 3.1%, acquisitions (net of divestitures) of 1.4% and a foreign currency translation gain of 1.3%.
Following the announcement, Labcorp’s shares edged up 0.7% in the pre-market session today.
Labcorp’s Q1 Performance by SegmentsThe company currently operates under two segments — Diagnostics Laboratories and Biopharma Laboratory Services (comprised of its Central Laboratories and Early Development Research Laboratories).
Diagnostics Laboratories reported revenues of $2.76 billion, reflecting a 5% improvement year over year.
On an organic basis, revenues were up 2.9%. The company’s total volumes (measured by requisitions) increased 2.5%, as acquisition volumes contributed 1.4% and organic volumes rose 1.1%.
Biopharma Laboratory Services revenues rose 8.2% to $780.6 million in the quarter. The year-over-year increase was primarily driven by organic growth of 3.7% and a foreign currency translation gain of 5.5%.
Labcorp’s Margin PerformanceThe gross margin expanded 32 basis points (bps) to 28.7% in the first quarter despite a 5.3% rise in the cost of revenues.
The adjusted operating income improved 15.1% year over year to $462.8 million. The adjusted operating margin expanded 106 bps year over year to 13.1% despite 0.9% rise in SG&A expenses ($551 million).
Labcorp’s Cash PositionLabcorp exited the first quarter of 2026 with cash and cash equivalents of $981.1 million compared with $532.3 million at the end of the fourth quarter of 2025. Long-term debt totaled $5.83 billion in the quarter.
Cumulative net cash provided by operating activities at the end of the first quarter was $191.5 million compared with $18.5 million a year ago.
Labcorp Holdings Inc. Price, Consensus and EPS SurpriseLH’s 2026 GuidanceLabcorp raised full-year 2026 enterprise revenue and adjusted EPS guidance. Enterprise-level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases and dividends.
Total revenues for 2026 are now expected to be in the range of $14.65-$14.80 billion (up from $14.61-$14.79 billion), representing growth of 5-6.1% (up from 4.7-6%). The Zacks Consensus Estimate for full-year revenues is pegged at $14.67 billion, representing growth of 5.2%.
Labcorp now expects 2026 adjusted EPS to be in the band of $17.70-$18.35 (up from $17.55-$18.25). The Zacks Consensus Estimate for the metric is pegged at $17.67.
Our View on LH StockLabcorp exited the first quarter of 2026 with better-than-expected results, with both earnings and revenues beating estimates. All the business segments reported growth in the quarter.
Key growth drivers include the launch of an AI-powered real-world data platform with Amazon Web Services and Datavant to advance Alzheimer’s research, alongside the FDA-cleared Labcorp Fentanyl Visual Urine Test for rapid screening. During the first quarter, collaborations with PathAI enable the deployment of AISight, while work with Illumina expands access to advanced oncology genomic testing, improving precision in biomarker insights. Supported by the strong quarterly performance and multiple catalysts, management raised its 2026 outlook.
Meanwhile, expansion of both margins is encouraging.
LH’s Zacks Rank & Key PicksLabcorp currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Intuitive Surgical (ISRG - Free Report) and Phibro Animal Health (PAHC - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted EPS of $1.28, which surpassed the Zacks Consensus Estimate by 20.8%. Revenues of $826.4 million beat the Zacks Consensus Estimate by 4.9%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an earnings yield of 4.7% compared with the industry’s negative yield of 1.4%. The company’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 18.79%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, posted a first-quarter 2026 adjusted EPS of $2.50, exceeding the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion topped the Zacks Consensus Estimate by 6.2%.
ISRG has an earnings yield of 2.1% in contrast to the industry’s negative yield of 0.9%. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.82%.
Phibro Animal Health, carrying a Zacks Rank #2 at present, posted a second-quarter fiscal 2026 adjusted EPS of 87 cents, exceeding the Zacks Consensus Estimate by 27.01%. Revenues of $373.9 million outperformed the Zacks Consensus Estimate by 4.72%.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.1% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 20.15%.
A downtrend has been apparent in Labcorp Holdings (LH - Free Report) lately. While the stock has lost 6% over the past two weeks, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.
While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the future earnings of this medical laboratory operator is a solid fundamental factor that enhances the prospects of a trend reversal for the stock.
Understanding Hammer Chart and the Technique to Trade ItThis is one of the popular price patterns in candlestick charting. A minor difference between the opening and closing prices forms a small candle body, and a higher difference between the low of the day and the open or close forms a long lower wick (or vertical line). The length of the lower wick being at least twice the length of the real body, the candle resembles a 'hammer.'
In simple terms, during a downtrend, with bears having absolute control, a stock usually opens lower compared to the previous day's close, and again closes lower. On the day the hammer pattern is formed, maintaining the downtrend, the stock makes a new low. However, after eventually finding support at the low of the day, some amount of buying interest emerges, pushing the stock up to close the session near or slightly above its opening price.
When it occurs at the bottom of a downtrend, this pattern signals that the bears might have lost control over the price. And, the success of bulls in stopping the price from falling further indicates a potential trend reversal.
Hammer candles can occur on any timeframe -- such as one-minute, daily, weekly -- and are utilized by both short-term as well as long-term investors.
Like every technical indicator, the hammer chart pattern has its limitations. Particularly, as the strength of a hammer depends on its placement on the chart, it should always be used in conjunction with other bullish indicators.
Here's What Makes the Trend Reversal More Likely for LHThere has been an upward trend in earnings estimate revisions for LH lately, which can certainly be considered a bullish indicator on the fundamental side. That's because a positive trend in earnings estimate revisions usually translates into price appreciation in the near term.
Over the last 30 days, the consensus EPS estimate for the current year has increased 1.7%. What it means is that the sell-side analysts covering LH are majorly in agreement that the company will report better earnings than they predicted earlier.
If this is not enough, you should note that LH currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. And stocks carrying a Zacks Rank #1 or 2 usually outperform the market. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Moreover, a Zacks Rank of 2 for Labcorp is a more conclusive indication of a potential trend reversal, as the Zacks Rank has proven to be an excellent timing indicator that helps investors identify precisely when a company's prospects are beginning to improve.
Labcorp's full test menu will be available through Epic's Aura platform Integration builds on the successful deployment of Invitae genetic testing and accelerates access to the latest genetic and specialty diagnostics through Aura Collaboration will help reduce IT complexity, streamline lab ordering and improve access to diagnostic innovation for hospitals and health systems using Epic nationwide , /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with Epic, the nation's leading electronic health record (EHR) supporting hospitals and health systems. Through the collaboration, Labcorp's full test menu will be available through Aura, Epic's unified platform for ordering and receiving lab results. The integration will drive meaningful operational efficiencies, streamline lab ordering for clinicians and care teams, and improve access to diagnostic innovation for hospitals and health systems using Epic nationwide.
Reducing Complexity and Expanding Access to Testing and Diagnostic Innovation
Health systems often face lengthy, complex and time-consuming IT projects to integrate with laboratory partners. By leveraging Epic's Aura, the expansion will reduce the time, cost and ongoing maintenance typically required for lab interfaces. Building on the availability of Invitae genetic tests through Aura, part of Labcorp's diagnostic portfolio, health systems will be able to access Labcorp's full test menu and new tests as they are introduced directly within their existing Epic workflows.
"This expanded collaboration reflects how Labcorp is investing to meet the evolving needs of hospitals and health systems," said Bryan Vaughn, Executive Vice President and President of Diagnostics at Labcorp. "By simplifying lab integrations and delivering our full test menu directly within Epic workflows, we are expanding access and building a strong foundation for continued innovation."
Benefits for Clinicians and Health Systems
The expanded integration will deliver meaningful benefits including:
Simplified onboarding and maintenance – Aura's connectivity and content‑management capabilities reduce the effort required to onboard and maintain Labcorp's test menu, reducing integration complexity for hospitals and health systems. Seamless access within Epic workflows – Clinicians will be able to order Labcorp tests and receive discrete results directly within their Epic workflow, improving efficiency and reducing reliance on manual processes or workarounds. Broader access to Labcorp's full and evolving test menu, including new and advanced diagnostics. "Expanding Labcorp's use of Aura to include its full test menu makes it easy for clinicians to order the right test the first time, right from their workflow, so patients get accurate answers faster," said Sumit Rana, President of Epic.
To learn more about Labcorp's ongoing collaboration with Epic and future plans to advance diagnostic integration for hospitals and health systems, visit https://www.labcorp.com/organizations/epic.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements with respect to the expected utility and benefits of integrating Labcorp's full test menu into the Epic Aura platform.
Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.
The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS."
MyLabcorp connects lab results, educational content and AI-enabled features in a secure, personalized mobile experience Leverages OpenAI models designed to help users understand their results, ask questions and identify patterns over time , /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the launch of MyLabcorp™, an AI-powered mobile app that brings together lab results, AI-enabled features and clinical guideline-based content in a secure, personalized mobile experience. The app is designed to give users additional context about their health and support more informed conversations with healthcare providers.
MyLabcorp
MyLabcorp
MyLabcorp
MyLabcorp
MyLabcorp Meeting Demand for Clearer Health Information
As healthcare becomes increasingly consumer-driven, individuals are turning to AI tools to help interpret health information, from understanding lab results to determining next steps in care. According to a Labcorp survey, more than half of consumers (55%) view AI as important for understanding healthcare information, with many already using it to interpret lab results (41%) and understand test ranges (35%). However, many AI tools answer questions in isolation without broader clinical context. MyLabcorp aims to address this gap by enabling users to view their Labcorp test results alongside relevant educational content and AI-generated explanations based on available data over time.
"Consumers are increasingly turning to AI to help them make sense of their health, but trust and clinical context matter," said Amy Summy, EVP and chief marketing officer at Labcorp. "By bringing together Labcorp's deep scientific expertise with AI, MyLabcorp is designed to help individuals move beyond isolated results to gain deeper insights into their health and support more informed conversations with their healthcare providers."
A More Connected, Intuitive Way to Understand Health
Key features of MyLabcorp include:
Lab results over time – Users have access to their Labcorp test results in a mobile-friendly view that tracks trends over time. AI‑enabled insights – Users can chat with an AI assistant for real‑time, personalized explanations of lab results and lifestyle considerations based on available Labcorp test data. MyLabcorp's AI capabilities are powered in part by OpenAI's advanced reasoning models, enabling more natural, conversational interactions tailored to each user. Health education content – Users can explore clinically reviewed, guideline-based information across key health areas, including cardiometabolic health, mental health, digestion, kidney function and sexual health, integrated with lab results to show trends and provide additional context. Lab services and support – Users can view and schedule appointments, locate patient service centers, access results, shop for tests and manage billing. Secure, trusted experience – A HIPAA‑compliant platform built to protect personal health information and user data. "At Labcorp, we're investing in advanced technology and AI to make diagnostic insights more accessible, personalized and actionable, improving how people understand and manage their health," said Bola Oyegunwa, Ph.D., EVP and chief information and technology officer at Labcorp. "MyLabcorp reflects this approach by combining Labcorp's scientific expertise with OpenAI's models to help individuals better understand their results and identify patterns over time, all within a secure, trusted environment."
Availability of MyLabcorp1
MyLabcorp is now available in the Apple App Store and Google Play Store with additional features rolling out on an ongoing basis.
To learn more, visit https://www.labcorp.com/patients/mylabcorp
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements with respect to the expected utility and benefits of MyLabcorp.
Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.
The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS."
____________________________
1
MyLabcorp is designed to support understanding and wellness and does not provide medical diagnoses or treatment recommendations. Always consult a qualified healthcare professional with medical questions or concerns.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Labcorp Holdings (LH - Free Report) Headquartered in Burlington, NC, Labcorp Holdings, Inc. or Labcorp, is a leading healthcare diagnostics company, providing comprehensive clinical laboratory services and end-to-end drug development support. In 2015, Labcorp acquired NJ based Covance, a drug development services company providing a wide range of early stage and late-stage product development services on a worldwide basis primarily to the pharmaceutical and biotechnology industries.
LH is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 14.1; value investors should take notice.
10 analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.36 to $17.99 per share. LH boasts an average earnings surprise of +3.3%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, LH should be on investors' short list.
Key Takeaways Labcorp expanded specialty testing in oncology, neurology and genetic testing to drive growth.LH invested $202M in acquisitions and expanded partnerships with Roche, SOMOS and PathAI.Labcorp expects 2026 revenue growth of 5.4% as earnings estimates rose 1.9% in 30 days. Labcorp Holdings Inc. (LH - Free Report) or Labcorp’s ongoing momentum in the high-growth specialty testing areas continues to support its prospects. The company is strengthening its position as a top partner for health systems and regional local laboratories to expand access to its broad test portfolio. It leverages AI and advanced technologies to enhance margins and customer experience. Yet, macroeconomic headwinds and currency fluctuations may hurt Labcorp’s results of operations.
Over the past year, this Zacks Rank #2 (Buy) stock has risen 5.5% compared with the industry’s 1.9% jump and the S&P 500 composite’s 32.5% growth.
The renowned healthcare diagnostics company has a market capitalization of $21.11 billion. LH has an earnings yield of 7% compared with the industry’s 4.4% yield. Labcorp surpassed earnings estimates in each of the trailing four quarters, the average surprise being 3.3%.
Let’s dive deeper.
Tailwinds for LabcorpFocus on High-Growth Areas: Labcorp continues to expand its business in specialty testing areas such as oncology, women’s health, autoimmune disease and neurology, which are expected to grow up to three times faster than other therapeutic areas. The company supported the development of more than 85% of new drugs approved by the FDA last year, including in these core specialty areas. Neurology experienced double-digit growth in the first quarter of 2026, driven by an expanded Alzheimer's testing portfolio. Oncology growth was supported by the launch of several liquid biopsy tests and expanded access to MRD solutions over the past year.
Image Source: Zacks Investment Research
The integration of Invitae has further expanded its reach in genetic testing solutions. Labcorp is also collaborating with Illumina to advance precision oncology through applications of next-generation sequencing (NGS) solutions across the healthcare ecosystem. The consumer health platform, Labcorp OnDemand, delivered double-digit growth in the first quarter, supported by its expanded offerings.
Strategic Acquisitions and Partnerships to Drive Growth: In recent years, Labcorp has built a significant number of strategic relationships with health systems and regional/local laboratories, expanding its patient and provider network, and strengthening its presence in key markets. In the first quarter of 2026, it invested $202 million in acquisitions. Enterprise revenues grew 5.8% year over year, with net acquisitions contributing 1.4%.
Recent activities include the purchase of select assets of Crouse Health’s Laboratory Alliance of Central New York’s (Lab Alliance) laboratory business and an agreement to manage their daily inpatient lab operations. Labcorp completed the acquisition of select assets of New York-based Empire City Laboratories. LH is the first U.S. commercial laboratory with an agreement to implement Roche’s cobas Mass Spec solution, which automates the entire workflow, from sample preparation to result interpretation. The company also signed a new multi-year partnership agreement with SOMOS, one of the largest Independent Practice Associations (IPAs) of community-based primary care and specialty providers in New York.
Focus on Operational Efficiency: Labcorp continues to benefit from its launchpad initiatives, which target $100-$125 million in savings annually. In the first quarter of 2026, the company expanded its collaboration with PathAI to deploy an FDA-cleared digital pathology platform across its national anatomic pathology labs and hospital lab partnerships. Together with Amazon Web Services and Datavant, Labcorp is developing a new AI-powered real-world data platform to accelerate Alzheimer's research.
More recently, Labcorp teamed up with Optum.ai to simplify laboratory operations by advancing AI. Across its core operations, AI and automation are already deployed in areas such as pathology, cytology and microbiology. Labcorp’s generative AI tool, Test Finder, is designed to simplify lab test selection and is also integrated into Labcorp Diagnostic Assistant.
What Ails LH Stock?Exposed to Currency Headwind: Labcorp's huge exposure in international markets makes it vulnerable to currency fluctuations. With the recent upward trend observed in the value of the U.S. dollar, further acceleration expected by analysts in this value will cause the company’s revenues to face a tough situation overseas.
Macroeconomic Risks: Labcorp’s operations are heavily dependent on the demand for diagnostic testing and drug development services from patients, physicians, hospitals, medical device companies and others. In recent times, volatilities in global economic conditions, including inflation, have significantly reduced the demand for these services, affecting the customers’ ability to pay and the company’s profitability. Added to this, the escalation of the present geopolitical tensions and retaliatory tariffs is putting pressure on the supply chain and services, increasing the prices of offerings.
LH Stock Estimate TrendOver the past 30 days, the Zacks Consensus Estimate for Labcorp’s 2026 earnings has increased 1.9% to $17.99.
The Zacks Consensus Estimate for 2026 revenues is pegged at $14.70 billion, suggesting a 5.4% improvement from the prior year.
Key PicksSome better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Align Technology (ALGN - Free Report) and Integra LifeSciences (IART - Free Report) .
Globus Medical has an earnings yield of 6.1% compared to the industry’s negative 1.1% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 26.3%. GMED shares have rallied 43.5% against the industry’s 4.2% fall over the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology, carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 10.3% for fiscal 2026 compared with the industry’s 9.5% growth. Shares of the company have dropped 4.6% compared to the industry’s 3.7% rise. ALGN’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 7.8%.
Integra LifeSciences, carrying a Zacks Rank #2, has an earnings yield of 15.7% against the industry’s negative 15.7% yield. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 16.7%. IART shares have rallied 23% against the industry’s 4.2% decline over the past year.
Investors might want to bet on Labcorp Holdings (LH - Free Report) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.
The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.
Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.
As such, the Zacks rating upgrade for Labcorp is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.
Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.
Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Labcorp imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.
Harnessing the Power of Earnings Estimate RevisionsEmpirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .
Earnings Estimate Revisions for LabcorpThis medical laboratory operator is expected to earn $17.99 per share for the fiscal year ending December 2026, which represents no year-over-year change.
Analysts have been steadily raising their estimates for Labcorp. Over the past three months, the Zacks Consensus Estimate for the company has increased 1.9%.
Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
You can learn more about the Zacks Rank here >>>
The upgrade of Labcorp to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that the company will present at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, from 12:15 pm to 12:45 pm ET.
The presentation can be accessed via a live webcast on the Labcorp Investor Relations website at ir.labcorp.com. An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed for 90 days following the event.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.
Investors looking for stocks in the Medical Services sector might want to consider either Labcorp Holdings (LH) or Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?
New pharmacogenomic test detects all DPYD variants recommended by the Association for Molecular Pathology to support safer, more personalized cancer treatment
, /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the availability of its expanded DPYD Genotyping test to help identify cancer patients who may be at increased risk for severe or life-threatening side effects from fluoropyrimidine chemotherapy. Labcorp now offers genotype testing for all DPYD Tier 1 and Tier 2 variants recommended by the Association for Molecular Pathology (AMP).
"Advances in pharmacogenomics are reshaping cancer care," said Marcia Eisenberg, Ph.D., chief scientific officer at Labcorp. "Our expanded DPYD test identifies patients at risk for severe toxicity before treatment begins, supporting safer, more personalized care. This expansion also strengthens Labcorp's pharmacogenomics and oncology portfolio, complementing the company's hereditary cancer testing, screening, diagnostic and precision oncology offerings to support more personalized cancer care across the patient journey."
Addressing a Significant Risk in Chemotherapy
Some patients experience preventable severe toxicity and death from chemotherapy intended to treat their cancer. Fluoropyrimidines, including 5-fluorouracil (5-FU) and capecitabine, are chemotherapy agents widely used to treat cancers including colorectal, pancreatic, upper gastrointestinal, breast, and head and neck. However, approximately 9% of patients carry a DPYD variant that can impair their ability to break down these drugs, increasing the risk of severe toxicity, and contributing to an estimated 1,300 deaths in the United States each year from 5-FU toxicity.
The DPYD gene encodes the enzyme DPD, which metabolizes more than 80% of 5-FU. Patients with reduced or absent DPD activity can experience serious, potentially life-threatening side effects, including diarrhea, neutropenia and neurotoxicity when exposed to 5-FU or capecitabine.
Updated U.S. Food and Drug Administration (FDA) product labeling for 5-FU and capecitabine includes a Boxed Warning about the risk of severe adverse reactions or death in patients with complete DPD deficiency. The FDA also advises testing for DPYD variants before treatment with 5-FU or capecitabine unless immediate treatment is necessary and recommends avoiding use of these drugs in patients with certain homozygous or compound heterozygous DPYD variants associated with complete DPD deficiency. Recent updates to National Comprehensive Cancer Network (NCCN) guidelines for colon cancer and other relevant indications reference these Boxed Warnings and the recommendation for DPYD testing. Clinical Pharmacogenomics Implementation Consortium (CPIC) guidelines further recommend adjusting or avoiding treatment based on a patient's DPYD metabolizer status as determined by DPYD testing.
Building on Leadership in Pharmacogenomics
Labcorp has offered DPYD testing since 2006 and offers pharmacogenomic testing across multiple specialty areas, including oncology, cardiology, neurology, women's health, pain management, gastroenterology and transplantation, helping providers use genetic information to tailor therapy, reduce preventable harm and support more personalized care.
The test is available to clinicians through Labcorp. For more information, visit https://www.labcorp.com/tests/512275/dpyd-genotyping
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.
Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members
Research will also assess the clinical impact of broader genetic testing in colorectal cancer care
, /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with the Alliance for Clinical Trials in Oncology to advance a national, multicenter clinical trial for patients newly diagnosed with colorectal cancer (CRC). The trial will evaluate approaches to increase germline genetic testing among at-risk family members, as well as the impact of multigene panel testing on care for newly diagnosed patients. Leveraging its Invitae testing, Labcorp will serve as the exclusive genetic testing provider, supporting participating sites with its national scale and scientific expertise.
Inherited genetic variants contribute to approximately 10% of all colorectal cancer cases. Testing family members of individuals with an inherited cancer-associated variant, called cascade testing, is a well-established approach to cancer prevention—particularly for Lynch syndrome, the most common hereditary colorectal cancer syndrome. However, studies indicate that less than one third of at-risk relatives receive recommended genetic testing.
The trial will assess whether proactive outreach by healthcare providers, rather than relying on patients to communicate genetic risk to their relatives, can improve participation of first-degree relatives in cascade genetic testing. In parallel, the trial will assess the impact of multigene panel testing on care for patients newly diagnosed with colorectal cancer.
"Genetic testing is a critical tool for identifying inherited cancer risk and guiding care for patients and their families, but too often at-risk relatives are not getting tested," said Shakti Ramkissoon, M.D., Ph.D., vice president, medical lead for oncology at Labcorp. "By supporting this trial and serving as the exclusive genetic testing provider, Labcorp is helping generate real-world evidence on how healthcare providers can connect families to genetic testing and follow-up care."
The trial is sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and led and conducted by the Alliance for Clinical Trials in Oncology. It includes participation from the NCI National Clinical Trials Network, which comprises academic medical centers, community oncology health systems and NCI-designated cancer centers. The study is expected to enroll patients and their relatives nationwide, including sites in Puerto Rico.
"By involving cancer care providers across our network, this study aims to evaluate a practical approach that can strengthen genetic risk identification for patients and their families," noted Frank A. Sinicrope, MD, from the Mayo Clinic and Heather Hampel, MS, CGC, from City of Hope, who are co-lead investigators for the trial. "The findings have the potential to help shape how genetic testing results are communicated to at-risk relatives in patients with colorectal cancer who have hereditary cancer syndromes nationwide."
This collaboration reflects Labcorp's continued commitment to advancing genetics-based approaches to improve outcomes for patients with cancer, while supporting high-impact clinical research in collaboration with leading research organizations.
For more information on the clinical trial, visit https://clinicaltrials.gov/study/NCT07143487 or view Alliance A212101 at https://www.allianceforclinicaltrialsinoncology.org/main/public/standard.xhtml?path=%2FPublic%2FFeatured-Trials
To learn more about Labcorp's hereditary cancer panels, visit https://www.invitae.com/us/providers/oncology/personalize-cancer-treatment
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at labcorp.com.
Key Takeaways Labcorp teamed with Alliance for Clinical Trials in Oncology on a national colorectal cancer trial. Labcorp will provide exclusive Invitae genetic testing for patients and at-risk relatives.The NCI-sponsored study will assess outreach and multigene testing impacts on CRC care. Labcorp (LH - Free Report) recently teamed up with the Alliance for Clinical Trials in Oncology to advance a national, multicenter clinical trial for patients newly diagnosed with colorectal cancer (“CRC”). This collaboration reflects Labcorp's continued commitment to advancing genetics-based approaches to improve outcomes for patients with cancer, while supporting high-impact clinical research in collaboration with leading research organizations.
Predicting LH Stock Movement Following the NewsFollowing the announcement, Labcorp’s shares edged down 0.7%, finishing at $260.06 last Friday.
In recent years, Labcorp has built a significant number of strategic relationships with health systems and regional/local laboratories, expanding the patient and provider network, and strengthening its presence in key markets. In the first quarter of 2026, enterprise revenues grew 5.8% year over year, with net acquisitions contributing 1.4%. We expect this latest development to drive positive market sentiment toward LH stock in the coming days.
Labcorp has a market capitalization of $21.32 billion. The company’s earnings yield of 5.9% compares favorably with the industry’s 4% yield. In the trailing four quarters, it delivered an average earnings surprise of 2.52%.
Significance of LH’s Collab for Multi-Institution TrialAccording to various sources, inherited genetic variants contribute to approximately 10% of all colorectal cancer cases. Testing family members of individuals with an inherited cancer-associated variant, called cascade testing, is a well-established approach to cancer prevention, particularly for Lynch syndrome, the most common hereditary colorectal cancer syndrome.
The trial will evaluate approaches to increase germline genetic testing among at-risk family members, as well as the impact of multigene panel testing on care for newly diagnosed patients. Leveraging its Invitae testing, Labcorp will serve as the exclusive genetic testing provider, supporting participating sites with its national scale and scientific expertise.
The trial will assess proactive outreach by healthcare providers which will improve participation of first-degree relatives in cascade genetic testing. In parallel, the trial will assess the impact of multigene panel testing on care for patients newly diagnosed with colorectal cancer.
About the Multi-Center CRC Genetic Testing TrialThe trial is sponsored by the National Cancer Institute (“NCI”) and led and conducted by the Alliance for Clinical Trials in Oncology. It includes participation from the NCI National Clinical Trials Network, which comprises academic medical centers, community oncology health systems and NCI-designated cancer centers. The study is expected to enroll patients and their relatives nationwide, including sites in Puerto Rico.
Industry Prospects Favor LHPer the Grand View Research report, the global hereditary cancer testing market size is projected to reach $14.45 billion by 2033, growing at a CAGR of 13.76% from 2025 to 2033. The demand for hereditary cancer testing is increasing due to technological advancements in genetic testing for cancer detection, integration with precision medicine and growing awareness through public and government initiatives.
Image Source: Zacks Investment Research
Another Recent Development By LHIn the previous week, Labcorp announced the availability of its expanded DPYD Genotyping test to help identify cancer patients who may be at increased risk for severe or life-threatening side effects from fluoropyrimidine chemotherapy.
LH Stock Price PerformanceIn the past year, LH’s shares have risen 5.4% compared with the industry’s 1% growth.
LH’s Zacks Rank and Key PicksLabcorp currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Integra LifeSciences (IART - Free Report) and Phibro Animal Health (PAHC - Free Report) .
Globus Medical has an earnings yield of 5.5%, well ahead of the industry’s negative 3% yield. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.3%. The company’s shares have rallied 43.8% against the industry’s 4.8% decline over the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Integra LifeSciences, carrying a Zacks Rank #2 (Buy) at present, has an earnings yield of 16% against the industry’s negative 3% yield. Shares of the company have gained 22.8% compared with the industry’s 4.8% growth. IART’s earnings topped estimates in each of the trailing four quarters, the average surprise being 16.8%.
Phibro Animal Health, carrying a Zacks Rank #2 at present, has an earnings yield of 9.2% compared with the industry’s 2.8% yield. Shares of the company have climbed 43.1% against the industry’s 27.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.3%.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Labcorp Holdings (LH - Free Report) Headquartered in Burlington, NC, Labcorp Holdings, Inc. or Labcorp, is a leading healthcare diagnostics company, providing comprehensive clinical laboratory services and end-to-end drug development support. In 2015, Labcorp acquired NJ based Covance, a drug development services company providing a wide range of early stage and late-stage product development services on a worldwide basis primarily to the pharmaceutical and biotechnology industries.
LH is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 14.5; value investors should take notice.
Nine analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.39 to $18.00 per share. LH boasts an average earnings surprise of +3.3%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, LH should be on investors' short list.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
